Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Holdings (NASDAQ:WGS) and increased the price target from $6 to $11.
April 15, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on GeneDx Holdings but raises the price target from $6 to $11.
The increase in the price target by Goldman Sachs suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100